Sun Pharmaceutical Industries Ltd

Large Cap

Healthcare Sector

reflects a positive outlook for the share price

reflects a neutral outlook for the share price

reflects a negative outlook for the share price

The analysts information is for reference only and does not\n  represents an investment recommendation.

Analyst recommendation reflect the views of analysts who follow and write research reports.

Revital

Volini

Abzorb

Pepfiz

Company Information is an introduction to the company’s business that details what it sell, how it was founded, what their mission is, how they manufacture or source their products, and why they serve customers.

Sun Pharmaceutical Industries is rated a Buy, with expected growth driven by specialty products. The company shows steady performance and is among top large-cap performers.

Sun Pharma Expected to Grow with Specialty Products - 15 Apr, 2026

Sun Pharmaceutical Industries achieved a significant legal victory as the Bombay High Court prohibited Meghmani Lifesciences from using the name 'Esiraft', citing trademark infringement. Additionally, Sun Pharma is expanding its presence in the weight-loss market with affordable generics of Ozempic and Wegovy.

Sun Pharma Secures Legal Victory Over Trademark - 13 Apr, 2026

Sun Pharmaceutical Industries is moving closer to a $12 billion acquisition of Organon, causing significant stock declines due to investor concerns over debt and integration risks.

Sun Pharma Faces Investor Caution Over Organon Acquisition - 10 Apr, 2026

Sun Pharmaceutical Industries Ltd is anticipated to drive domestic growth, while other firms may struggle with earnings due to export headwinds and cost pressures.

Sun Pharma Positioned for Domestic Growth Amid Challenges - 09 Apr, 2026

Sun Pharmaceutical Industries has appointed Satyavati Berera as an Independent Director for a term of five years, pending shareholder approval.

Sun Pharma Appoints New Independent Director - 04 Apr, 2026

Sun Pharmaceutical Industries is highlighted for its exposure to potential tariffs on patented drugs. Jefferies notes that while risks exist, the company's diversified manufacturing may limit the impact. Approximately 20% of its revenue comes from innovative medicines, but many products are produced in regions with lower tariff agreements.

Sun Pharma Faces Tariff Risks Amid Diverse Manufacturing - 03 Apr, 2026

Sun Pharmaceutical Industries Ltd saw a significant drop in shares due to potential US tariffs on imported medicines, particularly affecting its specialty products. The stock fell 6% as concerns grew over the impact on companies with high US exposure.

Sun Pharma Faces Decline Amid US Tariff Fears - 02 Apr, 2026

Sun Pharmaceutical Industries is experiencing positive momentum with reversal candles, trademark protection, and a court ruling against Intas. The stock is projected to reach Rs 2,065 in 8 to 10 months, supported by growth opportunities.

Sun Pharma Sees Positive Developments and Growth Potential - 30 Mar, 2026

Sun Pharmaceutical Industries announced mixed results from clinical trials for Fibromun and Nidlegy. The company is pursuing new studies and regulatory applications to enhance treatment options.

Sun Pharma Reports Mixed Trial Results and Updates - 28 Mar, 2026

On March 27, 2026, analysts recommended buying Sun Pharma shares, while the company showcased its dermatology research at the AAD Annual Meeting.

Sun Pharma Analysts Recommend Buy Amid AAD Meeting - 27 Mar, 2026

Analysts are optimistic about Sun Pharmaceutical Industries, with UBS maintaining a buy rating and adjusting the target price to Rs 2,200, while Krishan suggests a short-term buying opportunity at Rs 1,750.

Analysts Recommend Buy on Sun Pharma Amid Price Adjustments - 25 Mar, 2026

Faruqi & Faruqi is investigating DUSA Pharmaceuticals' Board for potential breaches related to its sale to Sun Pharma. Meanwhile, Citi maintains a BUY rating on Sun Pharma, citing strong quarterly performance and optimistic future earnings potential.

Sun Pharma Receives BUY Rating Amid DUSA Investigation - 24 Mar, 2026

Sun Pharmaceutical Industries has launched semaglutide injections, Noveltreat for weight management and Sematrinity for Type 2 diabetes, at competitive prices. The company also reported a significant rise in net profit and revenue for Q3 FY26.

Sun Pharma Launches Semaglutide Injections in India - 21 Mar, 2026

The rollout of semaglutide generics is anticipated, with five to six companies, including Sun Pharmaceutical, launching products. Price cuts by innovators may squeeze margins.

Semaglutide Generics Launch Impacting Market Dynamics - 19 Mar, 2026

Price to Earnings Ratio or Price to Earnings Multiple is the ratio of the share price of a stock to its earnings per share (EPS). It provides an indication of whether a stock at its current market price is expensive or cheap.

The price/earnings-to-growth ratio, or the PEG ratio, is a metric that helps investors value a stock by taking into account a company's market price, its earnings, and its future growth prospects.

Enterprise value (EV) is the total value of a company, defined in terms of its financing. It includes both the current share price (market capitalization) and the cost to pay off debt (net debt, or debt minus cash).

Alpha measures the amount that the investment has returned in comparison to the market index or other broad benchmark that it is compared against.

Beta measures a stock's volatility, the degree to which its price fluctuates in relation to the overall stock market. In other words, it gives a sense of the stock's risk compared to that of the greater market.

Dividend yield measures the quantum of earnings by way of total dividends that investors make by investing in that company.

The debt-to-total-assets ratio shows how much of a business is owned by creditors (people it has borrowed money from) compared with how much of the company's assets are owned by shareholders.

Operating cash flow (OCF) is a measure of the amount of cash generated by a company's normal business operations. Operating cash flow indicates whether a company can generate sufficient positive cash flow to maintain and grow its operations.

This widget shows the information about the stock's peers in consideration along with the different data for those peers so that the user can compare the stock with the other similar stock and invest accordingly.

Promoter holding is the amount of share of the company that is owned by the promoters. The promoters are the company's founders, who hold a majority stake in the company's capital.

A foreign institutional investor (FII) is an investor or investment fund investing in a country outside of the one in which it is registered or headquartered.

A mutual fund is a pool of money managed by a professional Fund Manager. It is a trust that collects money from a number of investors who share a common investment objective and invests the same in equities, bonds, money market instruments, and other securities.

Retail investors execute their trades through traditional or online brokerage firms or other types of investment accounts. Retail investors purchase securities for their own personal accounts and often trade in dramatically smaller amounts as compared to institutional investors.

This widget shows the bifurcation of stocks based on the percentage of stake with the different types of shareholders.

This widget will help value the stock based on the Price to Earning ratio of the stock and compare the valuation with the industry value and other similar stocks. It even shows the timeline of the valuation of the stock and its highest and lowest valuation over time.
A Time Series data is provided which compares the historical stock PE with Industry PE over the period of 5 years.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

Revenue is up for the last 4 quarters, 13.57K Cr → 16.09K Cr (in ₹), with an average increase of 5.5% per quarter

This section gives you an insight into how the revenue of the company has moved for the last few quarters.

Revenue Rich

Netprofit is up for the last 4 quarters, 2.14K Cr → 3.36K Cr (in ₹), with an average increase of 13.3% per quarter

This section gives you an insight into how the profit for the company has been for the last few quarters.

Profit Spike

Promoters holdings remained unchanged at 54.48% of holdings in Mar 2026 quarter

This section gives you an insight into how the Promoter Holding has changed for the stock over the last few quarters.

Promoter Holding Unchanged

In the last 3 years, Lupin Ltd has given 240.0% return, outperforming this stock by 170.3%

This section gives you an insight into how the peers have performed as compared to this company in the last 3 years.

Against Peers

In the last 1 year, Torrent Pharmaceuticals Ltd has given 28.4% return, outperforming this stock by 32.4%

This section gives you an insight into how the peers have performed as compared to this company in the last 1 year.

Mutual Funds have decreased holdings from 12.09% to 11.96% in Mar 2026 quarter

This section gives you an insight into how the Mutual Funds Holding has changed for the stock over last few quarters.

MF Holding Down

Foreign Institutions have decreased holdings from 16.12% to 15.93% in Mar 2026 quarter

This section gives you an insight into how the FII Holding has changed for the stock over last few quarters.

FII Holding Down

Retail Investor have decreased holdings from 8.58% to 8.48% in Mar 2026 quarter

This section gives you an insight into how the Retail Investors Holding has changed for the stock over last few quarters.

Retail Holding Down

In the last 1 month, SUNPHARMA stock has moved down by -5.7%

This section gives you an insight into the price movement of the stock for the last few quarters.

Price Dip

NIFTY PHARMA

BSE MFG

S&P BSE Low Volatility

NIFTY 50

S&P BSE SENSEX 50

Nifty Healthcare

S&P BSE 100 ESG

Nifty100 Low Volatility 30

SENSEX

BSE Healthcare

S&P BSE 100 LargeCap TMC

Nifty100 Eq Weig

Nifty LargeMidcap 250

Nifty 500

BSE 100

NIFTY 100

BSE 200

Nifty 200

S&P BSE Dividend Stability

S&P BSE 250 LargeMidCap

BSE 500

ICICI Prudential Value Fund Direct Plan Growth

ICICI Prudential Equity & Debt Fund Direct Plan Growth

ICICI Prudential Large Cap Fund Direct Plan Growth

HDFC Balanced Advantage Fund Direct Plan Growth Option

ICICI Prudential India Opportunities Fund Direct Growth

Sun Pharmaceutical Industries Ltd’s net profit jumped 16.03% since last year same period to ₹3,368.81Cr in the Q3 2025-2026. On a quarterly growth basis, Sun Pharmaceutical Industries Ltd has generated 8.05% jump in its net profits since last 3-months.

Sun Pharmaceutical Industries Ltd Earnings Results

In the quarter ending December 2025, Sun Pharmaceutical Industries Ltd has declared dividend of ₹11.00 per share on 31 Jan 2026 - translating a dividend yield of 1.61%.

Name	Value	Action
MACD level (12,26)	-0.42	Bearish
CCI (20)	143.51	Bearish
RSI (14)	47.94	Neutral
Momentum (10)	-1.1	Bullish
ADI (14)	25.04	Bearish
Ultimate Oscillator (7,14,28)	36.1	Neutral

Name	Value	Action
SMA (20)	1668.57	Bearish
EMA (20)	1668.24	Bearish
VWMA (20)	1668.11	Bearish
SMA (50)	1668.77	Bearish
EMA (50)	1668.72	Bearish
SMA (200)	1669.88	Bearish
EMA (200)	1670.02	Bearish
KAMA (200)	1669.52	Bearish
DEMA (200)	1668.26	Bearish

Sun Pharmaceutical Industries Ltd (SUNPHARMA)

Summary

Overall

Oscillators

Moving Averages